Adavosertib

Adavosertib alone and in combination with olaparib demonstrated efficacy among women with poly(ADP-ribose) polymerase (PARP) inhibitor-resistant ovarian cancer, according to study results presented during the virtual ASCO Annual Meeting.

Adavosertib demonstrated clinical activity among women with recurrent uterine serous carcinoma, according to results of a phase 2 study published in Journal of Clinical Oncology.